Skip to main content
Clinical Trials/NCT01089270
NCT01089270
Unknown
Not Applicable

Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives

Tel-Aviv Sourasky Medical Center1 site in 1 country80 target enrollmentMarch 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Tel-Aviv Sourasky Medical Center
Enrollment
80
Locations
1
Last Updated
16 years ago

Overview

Brief Summary

Parkinson Disease is one of the most common neurodegenerative illnesses. First degree relatives of Parkinson patient are in high risk for developing the disease. We will try to detect early changes in brain metabolism before the appearance of Parkinson symptoms.

Participants: first degree relatives of diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes.

The examination results will be given to the participants by a doctor from the neurology department.

Registry
clinicaltrials.gov
Start Date
March 2010
End Date
March 2011
Last Updated
16 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • healthy first degree relatives of diagnosed Parkinson patients

Exclusion Criteria

  • patients unable to understand and sign an informed consent
  • people with psychiatric disorders or a history of major head trauma

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials